Revvity (RVTY)

Company Profile

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, the company delivers unique solutions to serve the diagnostics, life sciences, food, and applied markets. IT strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.

Company profile

Ticker

RVTY, PKI

Exchange

NYSE

Website

www.perkinelmer.com

CEO

Prahlad Singh

Incorporated

Massachusetts

Location

Massachusetts

Fiscal year end

Dec 29

Sector

Manufacturing > Analytical Laboratory Instrument Manufacturing

Industry (SIC)

Laboratory Analytical Instruments

Agilent • Bio-Rad Laboratories • Waters • Illumina • Avantor • Mettler-Toledo International • Bruker • Seer • Prenetics Global Limited • Cue Health ...

Former names

EG&G INC, PERKINELMER INC

SEC CIK

0000031791

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

2Cure, LLC • BioLegend CNS, Inc. • BioLegend Ventures, LLC • BioLegend, Inc. • Caliper Life Sciences, Inc. • Cambridge Research • Dharmacon, Inc. • Horizon Discovery, Inc. • Immunodiagnostic Systems Inc. • Nexcelom Bioscience Holdings, LLC ...

IRS number

42052042

RVTY stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$146.25

Low target

$125.00

High target

$165.00

Latest filings (excl ownership)

View all

Conflict minerals disclosure

12 May 23

Results of Operations and Financial Condition

11 May 23

8-K

Amendments to Articles of Incorporation or Bylaws

28 Apr 23

8-K

Entry into a Material Definitive Agreement

15 Mar 23

ARS

2023 FY

Annual report to shareholders

8 Mar 23

DEFA14A

Additional proxy soliciting materials

8 Mar 23

1 Mar 23

Results of Operations and Financial Condition

14 Feb 23

Transcripts

View all

RVTY

Earnings call transcript

2023 Q1

11 May 23

RVTY

Earnings call transcript

2022 Q3

8 Nov 22

RVTY

Earnings call transcript

2022 Q2

5 Aug 22

RVTY

Earnings call transcript

2022 Q1

4 May 22

RVTY

Earnings call transcript

2021 Q4

2 Feb 22

RVTY

Earnings call transcript

2021 Q3

3 Nov 21

RVTY

Earnings call transcript

2021 Q2

29 Jul 21

RVTY

Earnings call transcript

2021 Q1

5 May 21

RVTY

Earnings call transcript

2020 Q4

3 Feb 21

RVTY

Earnings call transcript

2020 Q3

28 Oct 20

Latest ownership filings

View all

Michelle McMurry-Heath

Notice of proposed sale of securities

13 Apr 23

Financial summary

Financial statements Chart RVTY financial data

Quarter (USD)	Apr 23	Jan 23	Oct 22	Jul 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jan 23	Jan 22	Jan 21	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Revvity earnings reports.

Institutional ownership, Q1 2023

RVTY institutional ownership history Ownership history

82.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	540	594	-9.1%
Opened positions	45	105	-57.1%
Closed positions	99	42	+135.7%
Increased positions	203	194	+4.6%
Reduced positions	185	188	-1.6%

13F shares	Current	Prev Q	Change
Total value	13.70 tn	14.85 tn	-7.7%
Total shares	102.85 mm	106.04 mm	-3.0%
Total puts	79.00 k	52.00 k	+51.9%
Total calls	57.10 k	43.70 k	+30.7%
Total put/call ratio	1.4	1.2	+16.3%

Largest owners	Shares	Value	Change
Vanguard	14.68 mm	$1.96 tn	+2.0%
Capital Research Global Investors	11.84 mm	$1.58 tn	-7.9%
T. Rowe Price Investment Management	9.97 mm	$1.33 tn	+6.1%
Select Equity	9.94 mm	$1.32 tn	+1.6%
BLK Blackrock	8.58 mm	$1.14 tn	+1.2%
STT State Street	5.19 mm	$691.25 bn	-1.3%
Citadel Advisors	3.13 mm	$417.11 bn	+144.5%
Geode Capital Management	2.60 mm	$345.46 bn	+2.4%
Massachusetts Financial Services	2.29 mm	$304.55 bn	-29.5%
JHG Janus Henderson	2.09 mm	$278.77 bn	+0.3%

Largest transactions	Shares	Bought/sold	Change
T. Rowe Price	178.28 k	-2.03 mm	-91.9%
Citadel Advisors	3.13 mm	+1.85 mm	+144.5%
Norges Bank	0.00	-1.36 mm	EXIT
Pictet Asset Management	2.01 mm	-1.14 mm	-36.2%
Alliancebernstein	283.22 k	-1.14 mm	-80.1%
Point72 Asset Management	1.34 mm	+1.10 mm	+465.4%
Capital Research Global Investors	11.84 mm	-1.02 mm	-7.9%
Massachusetts Financial Services	2.29 mm	-957.88 k	-29.5%
Robecosam	0.00	-755.50 k	EXIT
Millennium Management	0.00	-683.32 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RVTY insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
15 May 23	Chapin Samuel R.	Common Stock	Grant	Acquire A	No	No	955	15,789
15 May 23	Chapin Samuel R.	Common Stock	Grant	Acquire A	No	No	783	14,834
15 May 23	Michas Alexis P	Common Stock	Grant	Acquire A	No	No	1,372	60,584
15 May 23	Michas Alexis P	Common Stock	Grant	Acquire A	No	No	1,061	59,212
15 May 23	Witney Frank	Common Stock	Grant	Acquire A	No	No	955	16,467
15 May 23	Witney Frank	Common Stock	Grant	Acquire A	No	No	783	15,512
15 May 23	Gregoire Sylvie	Common Stock	Grant	Acquire A	No	No	955	20,482
15 May 23	Gregoire Sylvie	Common Stock	Grant	Acquire A	No	No	783	19,527
15 May 23	Barrett Peter	Common Stock	Grant	Acquire A	No	No	955	21,406
15 May 23	Barrett Peter	Common Stock	Grant	Acquire A	No	No	783	20,451